Casdin Capital 13F holdings, Q1 2019
Holdings as of March 31, 2019 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 29 US equity positions worth $910.4m in its Q1 2019 13F filing. The largest position was SPARK THERAPEUTICS INC at 11.8% of the reported book, followed by 2655787D and MYOKARDIA INC. Against the Q4 2018 filing, it opened 2 new positions, added to 9 and reduced 4 among the top 29 holdings.
What did Casdin Capital own in Q1 2019? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2018 |
|---|---|---|---|---|---|---|---|
| 1 | SPARK THERAPEUTICS INC | 11.8% | $107.0m | 940,000 | 12% | added | |
| 2 | 2655787D BLUEPRINT MEDICINES CORP | 7.5% | $67.9m | 848,648 | 33% | added | |
| 3 | MYOKARDIA INC | 7.3% | $66.8m | 1,285,000 | 63% | added | |
| 4 | SG7 SAGE THERAPEUTICS INC | 7.0% | $63.6m | 400,000 | 28% | added | |
| 5 | BLUEBIRD BIO INC | 6.2% | $56.2m | 357,500 | 8% | added | |
| 6 | INVITAE CORP | 5.7% | $51.5m | 2,200,000 | -8% | reduced | |
| 7 | FATE FATE THERAPEUTICS INC | Healthcare | 4.9% | $44.8m | 2,550,000 | 0% | held |
| 8 | MAGENTA THERAPEUTICS INC | 4.8% | $43.5m | 2,643,318 | 0% | held | |
| 9 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 4.8% | $43.4m | 2,428,571 | 0% | held |
| 10 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.6% | $41.6m | 445,000 | 25% | added |
| 11 | CDXS CODEXIS INC | Healthcare | 4.6% | $41.6m | 2,025,000 | 0% | held |
| 12 | AUDENTES THERAPEUTICS INC | 4.3% | $39.4m | 1,010,000 | 17% | added | |
| 13 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 4.0% | $36.4m | 305,000 | 103% | added |
| 14 | GNMK GENMARK DIAGNOSTICS INC | 2.6% | $23.9m | 3,365,000 | -12% | reduced | |
| 15 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.5% | $22.6m | 335,000 | -25% | reduced |
| 16 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.4% | $21.6m | 1,128,075 | 0% | held |
| 17 | CNST CONSTELLATION PHARMCETICLS I | 2.3% | $21.1m | 1,556,999 | 0% | held | |
| 18 | ILMN ILLUMINA INC | Healthcare | 2.0% | $18.6m | 60,000 | 0% | held |
| 19 | GLOBAL BLOOD THERAPEUTICS IN | 1.7% | $15.9m | 300,000 | -14% | reduced | |
| 20 | 2JQ GRITSTONE ONCOLOGY INC | 1.6% | $14.9m | 1,120,586 | 56% | added | |
| 21 | EDIT EDITAS MEDICINE INC | Healthcare | 1.3% | $11.7m | 480,000 | 0% | held |
| 22 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.1% | $10.3m | 1,080,000 | 0% | held |
| 23 | HOMOLOGY MEDICINES INC | 1.1% | $9.7m | 350,000 | 0% | held | |
| 24 | ONC BEIGENE LTD | Healthcare | 1.0% | $9.2m | 70,000 | 0% | held |
| 25 | EVH EVOLENT HEALTH INC | Healthcare | 0.8% | $6.9m | 550,000 | 0% | held |
| 26 | CDNA CAREDX INC | Healthcare | 0.7% | $6.3m | 200,000 | 0% | held |
| 27 | ALEC ALECTOR INC | Healthcare | 0.7% | $6.2m | 331,039 | – | new |
| 28 | GILD GILEAD SCIENCES INC | Healthcare | 0.6% | $5.2m | 80,000 | – | new |
| 29 | DNLI DENALI THERAPEUTICS INC | Healthcare | 0.3% | $2.3m | 100,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.